0000000001070625

AUTHOR

Mar Juan

showing 1 related works from this author

Ceftolozane Pharmacokinetics in a Septic Critically Ill Patient under Different Extracorporeal Replacement Therapies

2019

Ceftolozane-tazobactam (C/T), a novel fifth-generation cephalosporin/β-lactamase inhibitor combination active against multidrug-resistant (MDR) Pseudomonas aeruginosa, is currently approved by the U.S. Food and Drug Administration (FDA) to treat complicated intra-abdominal and urinary tract

Adultmedicine.medical_specialtymedicine.drug_classCritical IllnessUrinary systemCephalosporinHemodiafiltrationMicrobial Sensitivity TestsOff-label usemedicine.disease_causeExtracorporealPharmacokineticspolycyclic compoundsmedicineHumansPseudomonas InfectionsPharmacology (medical)Intensive care medicineLetter to the EditorPharmacologyCritically illbusiness.industryPseudomonas aeruginosaPrecursor Cell Lymphoblastic Leukemia-Lymphomabacterial infections and mycosesAnti-Bacterial AgentsCephalosporinsInfectious DiseasesPseudomonas aeruginosaFemaleCeftolozanebusinessAntimicrobial Agents and Chemotherapy
researchProduct